Agents in development for the management of cocaine abuse

Drugs

Volumn 64, Issue 14, 2004, Pages 1547-1573

  Gorelick, David A ^a   Gardner, Eliot L ^a   Xi, Zheng Xiong ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ALLYL 2,3,4,5 TETRAHYDRO 1 PHENYL 1H 3 BENZAZEPINE 7,8 DIOL; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; ADROGOLIDE; AMPHETAMINE; BACLOFEN; BP 897; CABERGOLINE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE; COCAINE; DISULFIRAM; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; ECOPIPAM; FLUPENTIXOL; HALOPERIDOL; METHYLPHENIDATE; PIMOZIDE; RESERPINE; SELEGILINE; SEROTONIN AGONIST; SERTRALINE; TIAGABINE; UNINDEXED DRUG; VACCINE; VANOXERINE; VIGABATRIN;

ACTIVE IMMUNIZATION; BAY REGION BINDING SITE; CLINICAL TRIAL; COCAINE DEPENDENCE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; PHARMACOLOGICAL BLOCKING; REVIEW; SUSTAINED DRUG RELEASE; VACCINE PRODUCTION;

ANIMALS; CLINICAL TRIALS; COCAINE-RELATED DISORDERS; DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

ANIMALIA;

EID: 3242755117     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464140-00004     Document Type: Review

References (255)

1. United Nations Drug Control Program. Global illicit drug trends 2002. New York: United Nations Drug Control Program, 2002
2. Substance Abuse and Mental Health Services Administration. Results from the 2001 National Household Survey on drug abuse. Volume I: summary of national findings. Rockville (MD): Substance Abuse and Mental Health Services Administration, 2002. DHHS Publication No. SMA 01-3549, NHSDA Series: H-13
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
4. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Emergency department trends from the drug abuse network, final estimates 1994-2001. Rockville (MD): Substance Abuse and Mental Health Services Administration, 2002 Aug. DHHS Publication No. SMA 02-3635, DAWN Series D-21
5. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS): 1992-2000. National Admissions to Substance Abuse Treatment Services. Rockville (MD): Substance Abuse and Mental Health Services Administration, 2002 Dec. DHHS Publication No. SMA 02-3727, DASIS Series S-17
6. Gorelick DA. Pharmacological treatment of cocaine addiction. Einstein Q J Biol Med 1999; 16: 61-9
7. Gorelick DA. Pharmacologic interventions for cocaine, crack, and other stimulant addiction. In: Graham AW, Schultz TK, Mayo-Smith M, et al., editors. Principles of addiction medicine. 3rd ed. Chevy Chase (MD): American Society of Addiction Medicine, 2003: 89-111
8. de Lima MS, Soares BGO, Reisser AAP, et al. Pharmacological treatment of cocaine dependence: a systematic review. Addiction 2002; 97: 931-49
9. Lewin Group. Market barriers to the development of pharmacotherapies for the treatment of cocaine abuse and addiction: final report. Fairfax (VA): Lewin Group; 1997 Sep 12. Contract HHS-100-96-0011
10. Gorelick DA. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 1998; 42: 995-7
11. Dackis CA, O'Brien CP. Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat 2001; 21: 111-7
12. Platt DM, Rowlett JK, Spealman RD. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 2002; 163: 265-82
13. Wise RA, Gardner EL. Animal models of addiction. In: Charney DS, Nestler EJ, editors. Neurobiology of mental illness. 2nd ed. New York: Oxford University Press, 2004: 683-97
14. Gardner EL. What we have learned about addiction from animal models of drug self-administration. Am J Addict 2000; 9: 285-313
15. Shaham Y, Shalev U, Lu L, et al. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003; 168: 3-20
16. Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 1998; 56: 613-72
17. Colpaert FC. Drug discrimination in neurobiology. Pharmacol Biochem Behav 1999; 64: 337-45
18. Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci 1996; 19: 319-40
19. Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 1998; 54: 679-720
20. Vanderschuren LJMJ, Kalivas PW. Alterations in dopaminergic and glutamatergic signaling in the induction and expression of behavioral sensitization. Psychopharmacology 2000; 151: 99-120
21. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction 2001; 96: 103-14
22. Wise RA, Gardner EL. Functional anatomy of substance-related disorders. In: D'haenen H, den Boer JA, Willner P, editors. Biological psychiatry. New York: Wiley, 2002: 509-22
23. Howell LL, Wilcox KM. Functional imaging and neurochemical correlates of stimulant self-administration in primates. Psychopharmacology 2002; 163: 352-61
24. Volkow ND, Wang G-J, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997; 386: 827-30
25. Rothman RB, Glowa JR. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development: focus on GBR-12909. Mol Neurobiol 1995; 11: 1-19
26. Schweri MM, Deutsch HM, Massey AT, et al. Biochemical and behavioral characterization of novel methylphenidate analogs. J Pharmacol Exp Ther 2002; 301: 527-35
27. Carroll FI. 2002 Medicinal chemistry division award address: monoamine transporters and opioid receptors: targets for addiction therapy. J Med Chem 2003; 46: 1775-94
28. 3H]2β-carbomethoxy-3β-(fluorophenyl)tropane. Mol Pharmacol 1989; 36: 518-24
29. Woolverton WL, Rowlett JK, Wilcox KM, et al. 3′- and 4′-chloro-substituted analogs of benztropine: intravenous self-administration and in vitro radioligand binding studies in rhesus monkeys. Psychopharmacology 2000; 147: 426-35
30. Hsin LW, Dersch CM, Baumann MH, et al. Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: chiral hydroxyl-containing derivatives of 1-[2-[bis (4-fluorophenyl)methoxy] ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3- phenylpropyl)piperazine. J Med Chem 2002; 45: 1321-9
31. Froimowitz M, Wu K-M, Moussa A, et al. Slow-onset, long-duration 3-(3′,4′-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse. J Med Chem 2000; 43: 4981-92
32. Volkow ND, Ding Y-S, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995; 52: 456-63
33. Sizemore GM, Davies HM, Martin TJ, et al. Effects of 2beta-propanoyl- 3beta-(4-tolyl)-tropane (PTT) on the self-administration of cocaine, heroin, and cocaine/heroin combinations in rats. Drug Alcohol Depend 2004; 73: 259-65
34. Hemby SE, Co C, Reboussin D, et al. Comparison of a novel tropane analog of cocaine, 2 beta-propanoyl-3 beta-(4-tolyl) tropane with cocaine HCl in rats: nucleus accumbens extracellular dopamine concentration and motor activity. J Pharmacol Exp Ther 1995; 273: 656-66
35. Roberts DC, Jungersmith KR, Phelan R, et al. Effect of HD-23, a potent long acting cocaine-analog, on cocaine self-administration in rats. Psychopharmacology (Berl) 2003; 167(4): 386-92
36. Lile JA, Morgan D, Freedland CS, et al. Self-administration of two long-acting monoamine transport blockers in rhesus monkeys. Psychopharmacology (Berl) 2000; 152: 414-21
37. Wilcox KM, Lindsey KP, Votaw JR, et al. Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys. Synapse 2002; 43: 78-85
38. Dworkin SI, Lambert P, Sizemore GM, et al. RTI-113 administration reduces cocaine self-administration at high occupancy of dopamine transporter. Synapse 1998; 30: 49-55
39. Howell LL, Wilcox KM. The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther 2001; 298: 1-6
40. Mutschler NH, Bergman J. Effects of chronic administration of the D1 receptor partial agonist SKF 77434 on cocaine self-administration in rhesus monkeys. Psychopharmacology (Berl) 2002; 160: 362-70
41. Platt DM, Rowlett JK, Spealman RD. Dissociation of cocaine-antagonist properties and motoric effects of the D1 receptor partial agonists SKF 83959 and SKF 77434. J Pharmacol Exp Ther 2000; 293 (3): 1017-26
42. Caine SB, Negus SS, Mello NK, et al. Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. J Pharmacol Exp Ther 1999; 291: 353-60
43. 1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev 2001; 7: 305-16
44. Self DW, Karanian DA, Spencer JJ. Effects of the novel D1 dopamine receptor agonist ABT-431 on cocaine self-administration and reinstatement. Ann N Y Acad Sci 2000; 909: 133-44
45. Khroyan TV, Platt DM, Rowlett JK, et al. Attenuation of relapse to cocaine seeking by dopamine D1 receptor agonists and antagonists in non-human primates. Psychopharmacology (Berl) 2003; 168 (1-2): 124-31
46. Bergman J, Kamien JB, Spealman RD. Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. Behav Pharmacol 1990; 1: 355-63
47. Soyka M, De Vry J. Flupenthixol as a potential pharmacotreatment of alcohol and cocaine abuse/dependence. Eur Neuropsychopharmacol 2000; 10: 325-32
48. Glowa JR, Wojnicki FH. Effects of drugs on food- and cocaine-maintained responding, III: dopaminergic antagonists. Psychopharmacology (Berl) 1996; 128: 351-8
49. Schenk S, Gittings D. Effects of SCH 23390 and eticlopride on cocaine-seeking produced by cocaine and WIN 35,428 in rats. Psychopharmacology (Berl) 2003; 168: 118-23
50. Caine SB, Negus SS, Mello NK, et al. Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. J Neurosci 2002; 22: 2977-88
51. Garcia-Ladona FJ, Cox BF. BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine addiction. CNS Drug Rev 2003; 9: 141-58
52. Vorel SR, Ashby Jr CR, Paul M. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002; 22: 9595-603
53. Xi ZX, Gilbert J, Campos AC. Blockade of mesolimbic dopamine D(3) receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl) 2004 Apr 9 [Epub ahead of print]
54. Gardner EL, Ashby Jr CR. Heterogeneity of the mesotelencephalic dopamine fibers: physiology and pharmacology. Neurosci Biobehav Rev 2000; 24: 115-8
55. 3 dopamine receptors in the brains of several mammalian species. Brain Res 1998; 800: 269-74
56. 3 receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. J Pharmacol Exp Ther 2000; 294: 1166-74
57. Gardner EL. The neurobiology and genetics of addiction: implications of the 'reward deficiency syndrome' for therapeutic strategies in chemical dependency. In: Elster J, editor. Addiction: entries and exits. New York: Russell Sage, 1999: 57-119
58. Volkow ND, Fowler JS, Wang G-J. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 1999; 13: 337-45
59. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis 1987; 175: 641-52
60. Dixon L, Haas G, Weiden PJ, et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991; 148: 224-30
61. Ohuoha DC, Maxwell JA, Thomson III LE, et al. Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study. J Subst Abuse Treat 1997; 14: 249-58
62. Grabowski J, Rhoades H, Silverman P, et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol 2000; 20: 305-10
63. Di Chiara G. Drug addiction as a dopamine-dependent associative learning disorder. Eur J Pharmacol 1999; 375: 13-30
64. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural systems perspective. J Neurosci 2002; 22: 3312-20
65. Shalev U, Grimm JW, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 2002; 54: 1-42
66. Muller CP, Carey RJ, Huston JP. Serotonin as an important mediator of cocaine's behavioral effects. Drugs Today (Barc) 2003; 39 (7): 497-511
67. Uhl GR, Hall FS, Sora I. Cocaine, reward, movement and monoamine transporters. Mol Psychiatry 2002; 7 (1): 21-6
68. Walsh SL, Cunningham KA. Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology 1997; 130: 41-58
69. McGregor A, Lacosta S, Roberts DC. L-tryptophan decreases the breaking point under a progressive ratio schedule of intravenous cocaine reinforcement in the rat. Pharmacol Biochem Behav 1993; 44: 651-5
70. Carroll ME, Lac ST, Asencio M, et al. Intravenous cocaine self-administration in rats is reduced by dietary L-tryptophan. Psychopharmacology (Berl) 1990; 100: 293-300
71. Lee K, Kornetsky C. Acute and chronic fluoxetine treatment decreases the sensitivity of rats to rewarding brain stimulation. Pharmacol Biochem Behav 1998; 60: 539-44
72. Walsh SL, Cunningham KA. Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology (Berl) 1997; 130: 41-58
73. Schenk S. Effects of the serotonin 5-HT(2) antagonist, ritanserin, and the serotonin 5-HT(1A) antagonist, WAY 100635, on cocaine-seeking in rats. Pharmacol Biochem Behav 2000; 67: 363-9
74. Carey RJ, De Palma G, Damianopoulos E. 5-HT1A agonist/antagonist modification of cocaine stimulant effects: implications for cocaine mechanisms. Behav Brain Res 2002; 132: 37-46
75. Burmeister JJ, Lungren EM, Kirschner KF, et al. Differential roles of 5-HT receptor subtypes in cue and cocaine reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology 2004; 29: 660-8
76. Frankel PS, Cunningham KA. m-Chlorophenylpiperazine (mCPP) modulates the discriminative stimulus effects of cocaine through actions at the 5-HT2C receptor. Behav Neurosci 2004; 118: 157-62
77. Filip M, Cunningham KA. Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex. J Pharmacol Exp Ther 2003; 306: 734-43
78. Davidson C, Lee TH, Xiong Z, et al. Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. Neuropsychopharmacology 2002; 27: 542-53
79. Lane JD, Pickering CL, Hooper ML, et al. Failure of ondansetron to block the discriminative or reinforcing stimulus effects of cocaine in the rat. Drug Alcohol Depend 1992; 30: 151-62
80. Cervo L, Pozzi L, Samanin R. 5-HT3 receptor antagonists do not modify cocaine place conditioning or the rise in extracellular dopamine in the nucleus accumbens of rats. Pharmacol Biochem Behav 1996; 55: 33-7
81. Phillips GD, Robbins TR, Everitt BJ. Mesoaccumbens dopamine-opiate interactions in the control over behaviour of a conditioned reinforcer. Psychopharmacology 1994; 114: 345-59
82. Shippenberg TS, Chefer V. Opioid modulation of psychomotor stimulant effects. In: Maldonado R, editor. Molecular biology of drug addiction. Totowa (NJ): Humana Press, 2002: 107-33
83. Napier TC, Mitrovic I. Opioid modulation of ventral pallidal inputs. Ann N Y Acad Sci 1999; 877: 176-201
84. Akil H, Owens C, Gutstein H, et al. Endogenous opioids: overview and current issues. Drug Alcohol Depend 1998; 51: 127-40
85. Van Ree JM, Niesink RJ, Van Wolfswinkel L, et al. Endogenous opioids and reward. Eur J Pharmacol 2000; 405: 89-101
86. Okada Y, Tsuda Y, Bryant SD, et al. Endomorphins and related opioid peptides. Vitam Horm 2002; 65: 257-79
87. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions [published erratum appears in Nat Rev Drug Discov 2002 Nov; 1 (11): 920]. Nat Rev Drug Discov 2002; 1: 710-26
88. Kleber HD. Pharmacologic treatments for heroin and cocaine dependence. Am J Addict 2003; 12 Suppl. 2: S5-S18
89. Modesto-Lowe V, Van Kirk J. Clinical uses of naltrexone: a review of the evidence. Exp Clin Psychopharmacol 2002; 10: 213-27
90. Rademacher DJ, Steinpreis RE. Effects of the selective mu(1)-opioid receptor antagonist, naloxonazine, on cocaine-induced conditioned place preference and locomotor behavior in rats. Neurosci Lett 2002 Nov 8; 332 (3): 159-62
91. Ward SJ, Martin TJ, Roberts DC. Beta-funaltrexamine affects cocaine self-administration in rats responding on a progressive ratio schedule of reinforcement. Pharmacol Biochem Behav 2003 May; 75 (2): 301-7
92. Woolfolk DR, Holtzman SG. The effects of opioid receptor antagonism on the discriminative stimulus effects of cocaine and d-amphetamine in the rat. Behav Pharmacol 1996 Dec; 7 (8): 779-87
93. Mello NK, Negus SS. Interactions between kappa opioid agonists and cocaine: preclinical studies. Ann N Y Acad Sci 2000; 909: 104-32
94. Shippenberg TS, Chefer VI, Zapata A, et al. Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems. Ann N Y Acad Sci 2001; 937: 50-73
95. Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl) 2002; 161: 1-16
96. Kalivas PW. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Brain Res Rev 1993; 18 (1): 75-113
97. Kalivas PW, Duffy P, Eberhardt H. Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. J Pharmacol Exp Ther 1990; 253: 858-66
98. B agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 2002; 37 (5): 478-84
99. Dewey SL, Morgan AE, Ashby Jr CR, et al. A novel strategy for the treatment of cocaine addiction. Synapse 1998; 30 (2): 119-29
100. Dewey SL, Chaurasia CS, Chen CE, et al. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 1997; 25: 393-8
101. Kushner SA, Dewey SL, Kornetsky C. Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology (Berl) 1997; 133: 383-8
102. Kushner SA, Dewey SL, Kornetsky C. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. J Pharmacol Exp Ther 1999; 290: 797-802
103. Gardner EL, Schiffer WK, Horan BA, et al. Gamma-vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male rats. Synapse 2002; 46: 240-50
104. Panagis G, Kastellakis A. The effects of ventral tegmental administration of GABA(A), GABA(B), NMDA and AMPA receptor agonists on ventral pallidum self-stimulation. Behav Brain Res 2002; 131: 115-23
105. Willick ML, Kokkinidis L. The effects of ventral tegmental administration of GABAA, GABAB and NMDA receptor agonists on medial forebrain bundle self-stimulation. Behav Brain Res 1995; 70: 31-6
106. Negus SS, Mello NK, Fivel PA. Effects of GABA agonists and GABA-A receptor modulators on cocaine discrimination in rhesus monkeys. Psychopharmacology (Berl) 2000; 152: 398-407
107. Giorgetti M, Javaid JI, Davis JM, et al. Imidazenil, a positive allosteric GABAA receptor modulator, inhibits the effects of cocaine on locomotor activity and extracellular dopamine in the nucleus accumbens shell without tolerance liability. J Pharmacol Exp Ther 1998; 287: 58-66
108. Grant KA, Johanson CE. Diazepam self-administration and resistance to extinction. Pharmacol Biochem Behav 1987; 28: 81-6
109. Di Ciano P, Everitt BJ. The GABA(B) receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats. Neuropsychopharmacology 2003; 28: 510-8
110. Brebner K, Phelan R, Roberts DC. Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules. Psychopharmacology (Berl) 2000; 148: 314-21
111. Roberts DC, Brebner K. GABA modulation of cocaine self-administration. Ann N Y Acad Sci 2000; 909: 145-58
112. Brebner K, Froestl W, Andrews M, et al. The GABA(B) agonist CGP 44532 decreases cocaine self-administration in rats: demonstration using a progressive ratio and a discrete trials procedure. Neuropharmacology 1999; 38: 1797-804
113. Campbell UC, Lac ST, Carroll ME. Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. Psychopharmacology (Berl) 1999; 143: 209-14
114. Tzschentke TM, Schmidt WJ. Glutamatergic mechanisms in addiction. Mol Psychiatry 2003; 8: 373-82
115. Rockhold RW. Glutamatergic involvement in psychomotor stimulant action. Prog Drug Res 1998; 50: 155-92
116. Cornish JL, Kalivas PW. Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens. J Addict Dis 2001; 20: 43-54
117. Baker DA, McFarland K, Lake RW, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 2003; 6 (7): 743-9
118. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 2003; 23 (8): 3531-7
119. Xi Z-X, Ramamoorthy S, Shen H, et al. GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine. J Neurosci 2003; 23 (8): 3498-505
120. Xi Z-X, Ramamoorthy S, Baker DA, et al. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J Pharmacol Exp Ther 2002; 303: 608-15
121. Cornish JL, Kalivas PW. Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. J Neurosci 2000; 20 (15): RC89
122. Bell K, Duffy P, Kalivas PW. Context-specific enhancement of glutamate transmission by cocaine. Neuropsychopharmacology 2000; 23: 335-44
123. Shippenberg TS, Rea W, Slusher BS. Modulation of behavioral sensitization to cocaine by NAALADase inhibition. Synapse 2000 Nov; 38 (2): 161-6
124. Slusher BS, Thomas A, Paul M, et al. Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-acetylated-alpha-linked-acidic dipeptidase (NAALADASE). Synapse 2001 Jul; 41 (1): 22-8
125. Kotlinska J, Biala G. Memantine and ACPC affect conditioned place preference induced by cocaine in rats. Pol J Pharmacol 2000; 52: 179-85
126. Tzchentke TM, Schmidt WJ. Effects of the non-competitive NMDA-receptor antagonist memantine on morphine- and cocaine-induced potentiation of lateral hypothalamic brain stimulation reward. Psychopharmacology (Berl) 2000; 149: 225-34
127. Bespalov AY, Zvartau EE, Balster RL, et al. Effects of N-methyl-D-aspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats. Behav Pharmacol 2000; 11: 37-44
128. Hyytia P, Backstrom P, Liljequist S. Site-specific NMDA receptor antagonists produce differential effects on cocaine self-administration in rats. Eur J Pharmacol 1999; 378: 9-16
129. Kim JH, Vezina P. The mGlu2/3 receptor agonist LY379268 blocks the expression of locomotor sensitization by amphetamine. Pharmacol Biochem Behav 2002; 73 (2): 333-7
130. Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 1999; 291: 161-70
131. McGeehan AJ, Janak PH, Olive MF. Effect of the mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, d-amphetamine, and the dopamine reuptake inhibitor GBR12909 in mice. Psychopharmacology (Berl) 2004 Jan 15 [Epub ahead of print]
132. Kenny PJ, Paterson NE, Boutrel B, et al. Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann N Y Acad Sci 2003 Nov; 1003: 415-8
133. McGeehan AJ, Olive MF. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse 2003 Mar; 47 (3): 240-2
134. Chiamulera C, Epping-Jordan MP, Zocchi A, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2001; 4: 873-4
135. Baptista MA, Martin-Fardon R, Weiss F. Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer. J Neurosci 2004; 24: 4723-7
136. Pertwee RG. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs 2000; 9: 1553-71
137. Piomelli D, Giuffrida A, Calignano A, et al. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21: 218-24
138. Gardner EL. Addictive potential of cannabinoids: the underlying neurobiology. Chem Phys Lipids 2002; 121: 267-90
139. De Vries TJ, Shaham Y, Homberg JR, et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 2001; 7: 1151-4
140. Beinfeld MC. An introduction to neuronal cholecystokinin. Peptides 2001; 22: 1197-200
141. Noble F, Wank SA, Crawley JN, et al. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999; 51: 745-81
142. Vaccarino FJ. Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors. Neurosci Biobehav Rev 1994; 18: 207-14
143. Noble F, Roques BP. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol 1999; 58: 349-79
144. Josselyn SA, De Cristofaro A, Vaccarino FJ. Evidence for CCKA receptor involvement in the acquisition of conditioned activity produced by cocaine in rats. Brain Res 1997; 763: 93-102
145. Massey BW, Vanover KE, Woolverton WL. Effects of cholecystokinin antagonists on the discriminative stimulus effects of cocaine in rats and monkeys. Drug Alcohol Depend 1994; 34: 105-11
146. Crespi F. The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Methods Find Exp Clin Pharmacol 1998; 20: 679-97
147. Jackson A, Tattersall D, Bentley G, et al. An investigation into the discriminative stimulus and reinforcing properties of the CCKB-receptor antagonist, L-365,260 in rats. Neuropeptides 1994; 26 (5): 343-53
148. Lu L, Zhang B, Liu Z, et al. Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats. Brain Res 2002; 954: 132-40
149. Lu L, Liu D, Ceng X. Corticotropin-releasing factor receptor type 1 mediates stress-induced relapse to cocaine-conditioned place preference in rats. Eur J Pharmacol 2001; 415: 203-8
150. Goeders NE, Clampitt DM. Potential role for the hypothalamo-pituitary- adrenal axis in the conditioned reinforcer-induced reinstatement of extinguished cocaine seeking in rats. Psychopharmacology (Berl) 2002; 161: 222-32
151. Gurkovskaya O, Goeders NE. Effects of CP-154,526 on responding during extinction from cocaine self-administration in rats. Eur J Pharmacol 2001; 432: 53-6
152. Goeders NE, Guerin GF. Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. Neuropsychopharmacology 2000; 23: 577-86
153. Shaham Y, Erb S, Leung S, et al. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factorl receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl) 1998; 137: 184-90
154. Bissette G, Nemeroff CB. The neurobiology of neurotensin. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 573-82
155. Tyler BM, Douglas CL, Fauq A, et al. In vitro binding andCNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacology 1999; 38: 1027-34
156. Gully D, Canton M, Boigegrain R, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 1993; 90: 65-9
157. Gully D, Labeeuw B, Boigegrain R, et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther 1997; 280: 802-12
158. Binder EB, Kinkead B, Owens MJ, et al. Neurotensin and dopamine interactions. Pharmacol Rev 2001; 53: 453-86
159. Sarnyai Z, Shaham Y, Heinrichs SC. The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 2001; 53: 209-43
160. Sawchenko PE, Imaki T, Potter E, et al. The functional neuroanatomy of corticotropin-releasing factor. In: Chadwick DJ, Marsh J, Ackrill K, editors. Corticotropin-releasing factor. Chichester: Wiley, 1993: 5-29
161. Koob GF, Heinrichs SC. A role for corticotropin-releasing factor and urocortin in behavioral responses to stressors. Brain Res 1999; 848: 141-52
162. Piazza PV, Le Moal M. Pathophysiological basis of vulnerability to drug abuse: interaction between stress, glucocorticoids, and dopaminergic neurons. Annu Rev Pharmacol Toxicol 1996; 36: 359-78
163. Piazza PV, Le Moal M. Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications. Brain Res Rev 1997; 25: 359-72
164. Richter RM, Weiss F. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 1999; 32: 254-61
165. Sarnyai Z, Biro E, Gardi J, et al. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res 1995; 675: 89-97
166. Broadbear JH, Winger G, Rice KC, et al. Antalarmin, a putative CRH-RI antagonist, has transient reinforcing effects in rhesus monkeys. Psychopharmacology 2002; 164: 268-76
167. Henderson CE. Role of neurotrophic factors in neuronal development. Curr Opin Neurobiol 1996; 6: 64-70
168. Martin-Iverson MT, Todd KG, Altar CA. Brain-derived neurotrophic factor and neurotrophin-3 activate striatal dopamine and serotonin metabolism and related behaviors: interactions with amphetamine. J Neurosci 1994; 14: 1262-70
169. Horger BA, Iyasere CA, Berhow MT, et al. Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci 1999; 19: 4110-22
170. Grimm JW, Lu L, Hayashi T, et al. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 2003; 23: 742-7
171. Grimm JW, Hope BT, Wise RA, et al. Incubation of cocaine craving after withdrawal. Nature 2001; 412: 141-2
172. Carroll KM, Nich C, Ball SA, et al. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 2000; 95: 1335-49
173. Carroll KM, Ziedonis D, O'Malley SS, et al. Pharmacologic interventions for abusers of alcohol and cocaine: a pilot study of disulfiram versus naltrexone. Am J Addict 1993; 2: 77-9
174. Gorelick DA. Alcohol and cocaine: clinical and pharmacological interactions. Recent Dev Alcohol 1992; 11: 37-56
175. George TP, Chawarski MC, Pakes J, et al. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry 2000; 47: 1080-6
176. Petrakis IL, Carroll KM, Nich C, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000; 95: 219-28
177. Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61: 264-72
178. McCance-Katz EF, Kosten TR, Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biol Psychiatry 1998; 43: 540-3
179. Houtsmuller EJ, Notes LD, Newton T, et al. Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology 2004; 172: 31-40
180. Elkashef A, Fudala P, Gorgon S, et al. Transdermal selegiline for the treatment of cocaine dependence [poster]. Presented at College on Problems of Drug Dependence, 65th Annual Scientific Meeting; 2003 Jun 14-19; Bal Harbour
181. Montgomery A, Elkashef A, Ciraulo DA, et al. 2004 update of NIDA phase II medications development program for treatment of cocaine dependence [poster]. Presented at College on Problems of Drug Dependence, 66th Annual Scientific Meeting; 2004 Jun 12-17, San Juan
182. 18F-Dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002; 43: 201-7
183. Fava M, Rosenbaum JF, Kolsky AR, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol 1999; 19: 329-35
184. B receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 2002; 65: 209-20
185. Ling W, Shoptaw S, Majewska D. Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology 1998; 18: 403-4
186. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003; 64: 1440-8
187. Gonzalez G, Sevarino K, Sofuoglu M, et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 2003; 98: 1625-32
188. Gonzalez G, Sofuoglu M, Gonsai K, et al. Efficacy of tiagabine or gabapentin in reducing cocaine use in methadone-stabilized cocaine abusers [poster]. Presented at College on Problems of Drug Dependence, 65th Annual Scientific Meeting; 2003 Jun 14-19, Bal Harbour
189. Tennant F, Tarver A, Sagherian A, et al. A placebo-controlled elimination study to identify potential treatment agents for cocaine detoxification. Am J Addict 1993; 2: 299-308
190. Reid MS, Leiderman D, Casadonte P, et al. A controlled trial of olanzapine, valproate or coenzyme Q10/L-carnitine versus placebo for the treatment of cocaine dependence [abstract]. Drug Alcohol Depend 2000; 60 Suppl. 1: S179
191. Myrick H, Henderson S, Brady KT, et al. Divalproex loading in the treatment of cocaine dependence. J Psychoactive Drugs 2001; 33: 283-7
192. Halikas JA, Center BA, Pearson VL, et al. A pilot, open clinical study of depakote in the treatment of cocaine abuse. Hum Psychopharmacol 2001; 16: 257-64
193. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. In press
194. Brodie JD, Figueroa E, Dewey SL. Treating cocaine addiction: from preclinical to clinical trial experience with γ-vinyl GABA. Synapse 2003; 50: 261-5
195. Raby WN, Coomaraswamy S. Gabapentin reduces cocaine use among addicts from a community clinic sample. J Clin Psychiatry 2004; 65: 84-6
196. Bisaga A, Aharonovich E, Nune E. Gabapentin treatment of cocaine dependence [poster]. Presented at College on Problems of Drug Dependence, 65th Annual Scientific Meeting; 2003 Jun 14-19, Bal Harbour
197. Gonsai K, Oliveto A, Poling J, et al. Efficacy of sertraline in depressed, recently abstinent, cocaine-dependent patients [abstract]. Drug Alcohol Depend 2002; 66 Suppl. 1: S67
198. Pulvirenti L, Balducci C, Koob GF. Dextromethorphan reduces intravenous cocaine self-administration in the rat. Eur J Pharmacol 1997; 321: 279-83
199. Kilpatrick GJ, Tilbrook GS. Memantine: Merz. Curr Opin Investig Drugs 2002; 3: 798-806
200. Collins ED, Ward AS, McDowell DM, et al. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav Pharmacol 1998; 9: 587-98
201. Johnson BA, Devous MD, Ruiz P, et al. Treatment advances for cocaine-induced ischemic stroke: focus on dihydropyridine-class calcium channel antagonists. Am J Psychiatry 2001; 158: 1191-8
202. Gottschalk PCH, Kosten TR. Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits. Am J Addict 2002; 11: 200-8
203. Malcolm R, Brady KT, Moore J, et al. Amlodipine treatment of cocaine dependence. J Psychoactive Drugs 1999; 31: 117-20
204. Johnson BA, Roache JD, Wells L, et al. Sub-acute dosing with isradipine blocks cocaine euphoria and craving in phase II lab trials for medications to treat cocaine dependence. Drug Alcohol Depend 2002; 66 Suppl. 1: S86-7
205. Ait-Daoud N, Wells L, Roache JD, et al. Sub-acute dosing with isradipine modestly decreases pressor response in a phase II lab trials for medications to treat cocaine dependence [abstract]. Drug Alcohol Depend 2002; 66 Suppl. 1: S4
206. Batki SL, Bradley M, Moon J, et al. A controlled trial of isradipine in cocaine dependence: preliminary analysis [abstract]. NIDA Res Monogr 1998; 179: 56
207. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001; 21: 522-6
208. Grabowski J, Rhoades H, Schmitz J, et al. Methods for early phase medication development trials examined using the agonist approach for cocaine dependence [abstract]. Drug Alcohol Depend 2002; 66 Suppl. 1: S68
209. Shearer J, Wodak A, Van Beek I, et al. Pilot randomized double-blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003; 98: 1137-41
210. Walsh SL, Haberny KA, Bigelow GE. Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology 2000; 150: 361-73
211. Uemura N, Manari A, Shih K, et al. The safety and efficacy of sustained cocaine agonist exposures in suppressing cocaine craving and self-administration in humans. Drug Alcohol Depend 2002; 66 Suppl. 1: S185
212. Dackis C, O'Brien C. Glutamatergic agents for cocaine dependence. Ann N Y Acad Sci 2003; 1003: 328-45
213. Rush CR, Kelly TH, Hays LR, et al. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend 2002; 67: 311-22
214. Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000; 23: 149-56
215. Dackis C, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003; 70: 29-37
216. Malcolm RJ, Donovan JL, DeVane CL, et al. Influence of modafinil, 400 or 800 mg/day on subjective effects of intravenous cocaine in non-treatment-seeking volunteers [abstract]. Drug Alcohol Depend 2002; 66 Suppl. 1: S110
217. Camacho A, Stein MB. Modafinil for social phobia and amphetamine dependence. Am J Psychiatry 2002; 159: 1947-8
218. Malcolm R, Book SW, Moak D, et al. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am J Addict 2002; 11: 247-9
219. Kampman KM, Volpicelli JR, Mulvaney F, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001; 63: 69-78
220. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence [poster]. Presented at College on Problems of Drug Dependence, 66th Annual Scientific Meeting; 2004 Jun 12-17, San Juan
221. Compton PA, Ling W, Charuvastra VC, et al. Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. J Addict Dis 1995; 14: 97-114
222. Montoya I, Gorelick D, Preston K, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004; 75: 34-48
223. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res 2002; 70: 133-9
224. Clark WM, Wechsler LR, Sabounjian LA, et al. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001; 57: 1595-602
225. Penetar D, Rodolico J, Eaton J, et al. Citicoline treatment for cocaine dependence: safey and effects on sleep and subjective mood states [abstract]. Presented at College on Problems of Drug Dependence, 65th Annual Scientific Meeting; 2003 Jun 14-19; Bal Harbour
226. Lukas SE, Kouri EM, Rhee C, et al. Effects of short-term citicoline treatment on acute cocaine intoxication and cardiovascular effects. Psychopharmacology 2001; 157: 163-7
227. Majewska MD. HPA axis and stimulant dependence: an enigmatic relationship. Psychoneuroendocrinology 2002; 27: 5-12
228. Mendelson JH, Mello NK, Sholar MB, et al. Temporal concordance of cocaine effects on mood states and neuroendocrine hormones. Psychoneuroendocrinology 2002; 27: 71-82
229. Ward AS, Collins ED, Haney M, et al. Ketoconazole attenuates the cortisol response but not the subjective effects of smoked cocaine in humans. Behav Pharmacol 1998; 9: 577-86
230. Ward AS, Collins ED, Haney M, et al. Blockade of cocaine-induced increases in adrenocorticotrophic hormone and cortisol does not attenuate the subjective effects of smoked cocaine in humans. Behav Pharmacol 1999; 10: 523-9
231. Shoptaw S, Majewska MD, Wilkins J, et al. Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot study. Exp Clin Psychopharmacol 2004; 12: 126-35
232. Goeders NE. Stress and cocaine addiction. J Pharmacol Exp Ther 2002; 301: 785-9
233. Preti A. Vanoxerine: National Institute on Drug Abuse. Curr Opin Investig Drugs 2000; 1: 241-51
234. Cantilena LR, Haigney M, Elkashef A, et al. Clinical safety of multiple escalating doses of GBR12909 in healthy volunteers [abstract]. Drug Alcohol Depend 2001; 63 Suppl. 1: S24
235. Madras BK, Bendor JT, Meyerhoff AR, et al. The tropane horse: a novel cocaine antagonist strategy? [abstract]. Drug Alcohol Depend 2002; 66 Suppl. 1: S24
236. Woolverton WL, Ranaldi R, Wang Z, et al. Reinforcing strength of a novel dopamine transporter ligand: pharmacodynamic and pharmacokinetic mechanisms. J Pharmacol Exp Ther 2002; 303: 211-7
237. 1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology 1999; 143: 102-10
238. Eder DN. CEE-03-310 CeNeS pharmaceuticals. Curr Opin Investig Drugs 2002; 3: 284-8
239. Haney M, Ward AS, Foltin RW, et al. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology 2001; 155: 330-7
240. 1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology 2001; 155: 338-47
241. Neumeyer JL, Gu X-H, van Vliet LA, et al. Mixed κ agonists and μ agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg Med Chem Lett 2001; 11: 2735-40
242. Walsh SL, Geter-Douglas B, Strain EC, et al. Enadoline and butorphanol: evaluation of κ-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J Pharmacol Exp Ther 2001; 299: 147-58
243. Lavarone L, Hoke JF, Bottacini M, et al. First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol 1999; 39: 560-6
244. Gorelick DA. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 1997; 48: 159-65
245. Carmona GN, Schindler CW, Shoaib M, et al. Attenuation of cocaine-induced locomotor activity by butyrylcholinesterase. Exp Clin Psychopharmacol 1998; 6: 274-9
246. Carrera MRA, Ashley JA, Wirsching P, et al. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci U S A 2001; 98: 1988-92
247. Deng SX, de Prada P, Landry DW. Anticocaine catalytic antibodies. J Immunol Methods 2002; 269: 299-310
248. Sun H, Shen ML, Pang Y-P, et al. Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J Pharmacol Exp Ther 2002; 302: 710-6
249. Turner JM, Larsen NA, Basran A, et al. Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry 2002; 41: 12297-307
250. Kantak KM. Anti-cocaine vaccines: antibody protection against relapse. Expert Opin Pharmacother 2003; 4: 213-8
251. Ho M, Segre M. Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties. Biochim Biophys Acta 2003; 1638: 257-66
252. Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20: 1196-204
253. Kosten T. Immunotherapies for substance abuse: human cocaine vaccine [abstract]. Presented at College on Problems of Drug Dependence, 65th Annual Scientific Meeting; 2003 Jun 14-19; Bal Harbour
254. Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence [poster]. Presented at College on Problems of Drug Dependence, 66th Annual Scientific Meeting; 2004 Jun 12-17, San Juan
255. BioSpace. Large, unreachable markets? What biotechs are doing [online]. Available from URL: http://www.biospace.com/ articles/091699_biotechaddiction. cfm [Accessed 2002 Dec 11]